Go Pro
→ BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it? (From Awesomely) (Ad)tc pixel Free RCKTW Stock Alerts

Rocket Pharmaceuticals (RCKTW) Financials

Rocket Pharmaceuticals logo
$0.0028 0.00 (-6.60%)
As of 11:01 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Rocket Pharmaceuticals

Annual Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -7.57 -20 -75 -77 -140 -169 -222 -246 -259 -223
Consolidated Net Income / (Loss)		 -68 -7.57 -20 -75 -77 -140 -169 -222 -246 -259 -223
Net Income / (Loss) Continuing Operations		 -22 -7.57 -20 -76 -79 -140 -167 -222 -256 -267 -230
Total Pre-Tax Income 		-22 -7.57 -20 -76 -79 -140 -167 -222 -256 -267 -230
Total Operating Income		 -20 -7.57 -20 -71 -76 -134 -167 -224 -260 -273 -232
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 20 7.57 20 71 76 134 166 224 260 273 232
Selling, General & Admin Expense		 7.84 1.58 4.86 18 18 29 42 59 73 102 87
Research & Development Expense		 13 5.99 15 53 58 105 124 165 186 171 142
Restructuring Charge		 - - - - - - - - - 0.00 3.23
Total Other Income / (Expense), net		 -1.14 0.00 0.00 -4.35 -2.54 -5.40 0.09 2.03 3.41 6.38 1.33
Interest Expense		 1.23 0.00 0.00 6.04 5.96 6.97 2.98 1.86 1.88 1.89 1.89
Interest & Investment Income		 0.09 0.00 0.00 1.69 3.41 1.57 3.07 3.89 5.29 8.27 3.22
Other Adjustments to Consolidated Net Income / (Loss)		 - 0.00 0.19 0.80 1.43 - -2.91 -0.05 11 8.08 7.30
Basic Earnings per Share		 ($3.72) ($1.11) ($2.88) ($1.89) ($1.58) ($2.52) ($2.67) ($3.26) ($2.92) ($2.73) ($2.01)
Weighted Average Basic Shares Outstanding		 18.31M 6.83M 6.80M 39.38M 49.01M 55.38M 63.24M 68.15M 84.01M 94.81M 111.12M
Diluted Earnings per Share		 ($3.72) ($1.11) ($2.88) ($1.89) ($1.58) ($2.52) ($2.67) ($3.26) ($2.92) ($2.73) ($2.01)
Weighted Average Diluted Shares Outstanding		 18.31M 6.83M 6.80M 39.38M 49.01M 55.38M 63.24M 68.15M 84.01M 94.81M 111.12M
Weighted Average Basic & Diluted Shares Outstanding		 18.31M 6.83M 6.80M 39.38M 49.01M 55.38M 64.51M 79.35M 90.50M 106.63M 108.57M

Quarterly Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -62 -60 -62 -70 -67 -60 -61 -69 -50 -43 -48
Consolidated Net Income / (Loss)		 -62 -60 -62 -70 -67 -60 -61 -69 -50 -43 -48
Net Income / (Loss) Continuing Operations		 -64 -63 -65 -72 -69 -62 -64 -71 -52 -44 -49
Total Pre-Tax Income 		-64 -63 -65 -72 -69 -62 -64 -71 -52 -44 -49
Total Operating Income		 -65 -63 -67 -74 -69 -63 -64 -71 -52 -44 -49
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 65 63 67 74 69 63 64 71 52 44 49
Selling, General & Admin Expense		 19 22 22 27 27 25 28 25 18 15 17
Research & Development Expense		 47 42 45 46 42 37 36 43 34 29 31
Total Other Income / (Expense), net		 1.25 0.34 2.56 1.82 0.86 1.14 0.86 0.01 0.24 0.22 -0.31
Interest Expense		 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47
Interest & Investment Income		 1.72 0.81 3.03 2.29 1.33 1.62 1.34 0.48 0.71 0.69 0.16
Other Income / (Expense), net		 - - - - - - 0.00 - - - 0.00
Other Adjustments to Consolidated Net Income / (Loss)		 2.28 3.28 2.76 2.24 1.85 1.22 2.19 2.22 1.68 1.21 1.23
Basic Earnings per Share		 ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56) ($0.62) ($0.45) ($0.38) ($0.42)
Weighted Average Basic Shares Outstanding		 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M 111.02M 111.57M 111.12M 112.13M
Diluted Earnings per Share		 ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56) ($0.62) ($0.45) ($0.38) ($0.42)
Weighted Average Diluted Shares Outstanding		 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M 111.02M 111.57M 111.12M 112.13M
Weighted Average Basic & Diluted Shares Outstanding		 90.16M 90.50M 90.78M 90.98M 91.16M 106.63M 107.74M 107.90M 108.22M 108.57M 109.19M

Annual Cash Flow Statements for Rocket Pharmaceuticals

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 76 -5.82 -17 94 74 112 -65 -92 -85 108 -86
Net Cash From Operating Activities		 -17 -5.50 -16 -54 -65 -75 -121 -178 -195 -210 -190
Net Cash From Continuing Operating Activities		 -17 -5.50 -16 -54 -65 -75 -121 -178 -195 -210 -190
Net Income / (Loss) Continuing Operations		 -68 -7.57 -20 -75 -77 -140 -169 -222 -246 -259 -223
Consolidated Net Income / (Loss)		 -68 -7.57 -20 -75 -77 -140 -169 -222 -246 -259 -223
Depreciation Expense		 0.05 0.07 0.20 0.33 0.43 1.15 3.24 3.93 4.94 7.22 8.87
Amortization Expense		 0.08 0.00 0.00 3.06 3.60 8.44 5.77 2.33 -8.01 -5.91 -4.82
Non-Cash Adjustments To Reconcile Net Income		 50 0.48 1.32 13 12 46 42 32 40 42 37
Changes in Operating Assets and Liabilities, net		 0.67 1.52 2.09 4.22 -3.73 9.61 -3.58 6.02 14 5.49 -8.34
Net Cash From Investing Activities		 -32 -0.34 -0.76 -5.27 -39 -97 19 -69 -98 132 104
Net Cash From Continuing Investing Activities		 -32 -0.34 -0.76 -5.27 -39 -97 19 -69 -98 132 104
Purchase of Property, Plant & Equipment		 -0.41 -0.34 -0.76 -1.45 -23 -21 -7.62 -8.36 -16 -5.86 -0.44
Purchase of Investments		 -34 0.00 0.00 -141 -184 -209 -246 -376 -391 -246 -277
Sale of Property, Plant & Equipment		 - 0.00 0.00 0.02 - - - 0.00 0.00 0.14 0.00
Divestitures		 - 0.00 0.00 76 - 0.00 0.00 43 0.00 0.00 0.00
Sale and/or Maturity of Investments		 2.43 0.00 0.00 61 169 142 272 273 309 383 381
Other Investing Activities, net		 - 0.00 0.00 -0.38 0.00 -8.45 -0.10 -0.26 -0.04 0.00 0.00
Net Cash From Financing Activities		 126 0.02 25 154 178 283 38 155 208 186 0.15
Net Cash From Continuing Financing Activities		 126 0.02 0.00 154 178 283 38 155 208 186 0.00
Issuance of Common Equity		 112 0.00 0.00 154 178 281 26 155 206 183 0.00
Other Financing Activities, net		 - 0.03 0.00 0.15 -0.34 1.94 11 0.63 2.24 3.21 0.00
Cash Interest Paid		 0.09 0.00 0.00 4.49 2.99 2.96 0.15 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Rocket Pharmaceuticals

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 181 -170 -21 3.33 27 98 -114 -17 43 1.59 -28
Net Cash From Operating Activities		 -57 -29 -57 -54 -52 -47 -56 -49 -50 -35 -45
Net Cash From Continuing Operating Activities		 -57 -29 -57 -54 -52 -47 -56 -49 -50 -35 -45
Net Income / (Loss) Continuing Operations		 -62 -60 -62 -70 -67 -60 -61 -69 -50 -43 -48
Consolidated Net Income / (Loss)		 -62 -60 -62 -70 -67 -60 -61 -69 -50 -43 -48
Depreciation Expense		 1.22 1.40 1.72 1.83 1.85 1.82 2.45 2.04 2.70 1.68 1.61
Amortization Expense		 5.37 -9.63 -2.22 -4.46 -1.31 -0.68 -1.54 -3.75 -1.06 -0.55 0.54
Non-Cash Adjustments To Reconcile Net Income		 4.14 17 11 14 11 13 10 13 9.77 6.11 7.47
Changes in Operating Assets and Liabilities, net		 -6.00 22 -5.71 4.30 2.78 -0.75 -5.73 8.71 -12 0.18 -7.39
Net Cash From Investing Activities		 48 -141 35 56 79 -38 -58 32 94 36 17
Net Cash From Continuing Investing Activities		 48 -141 35 56 79 -38 -58 32 94 36 17
Purchase of Property, Plant & Equipment		 -4.66 -4.65 -2.04 -1.93 -1.59 -0.31 -0.36 -0.05 0.05 -0.08 -0.09
Purchase of Investments		 -13 -209 -64 -39 -19 -124 -140 -53 -29 -54 -49
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 66 72 101 96 100 86 82 85 123 91 66
Net Cash From Financing Activities		 189 0.39 1.18 1.53 0.18 183 0.00 0.22 -0.07 - -0.00
Net Cash From Continuing Financing Activities		 189 0.39 1.18 1.53 0.18 183 0.00 - - - 0.00

Annual Balance Sheets for Rocket Pharmaceuticals

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 113 130 20 251 372 591 497 552 566 528 330
Total Current Assets		 112 128 19 209 308 487 392 364 378 378 193
Cash & Equivalents		 80 30 18 111 185 297 233 141 56 164 78
Short-Term Investments		 31 97 0.00 94 119 186 156 216 317 209 111
Prepaid Expenses		 1.09 1.88 0.81 3.36 3.64 4.63 3.32 7.67 5.05 5.85 3.81
Plant, Property, & Equipment, net		 0.81 1.13 0.99 2.03 30 19 22 29 39 37 28
Total Noncurrent Assets		 0.14 0.17 0.21 40 35 84 83 159 148 113 110
Noncurrent Note & Lease Receivables		 - - - - 0.00 51 48 47 45 42 40
Goodwill		 - - 0.00 31 31 31 31 39 39 39 39
Intangible Assets		 - - - - - - 0.00 26 25 25 25
Other Noncurrent Operating Assets		 0.14 0.17 0.21 1.98 4.03 2.94 3.37 3.92 4.43 6.06 5.03
Total Liabilities & Shareholders' Equity		 113 130 20 251 372 591 497 552 566 528 330
Total Liabilities		 4.51 56 4.63 57 65 87 42 62 74 64 53
Total Current Liabilities		 4.14 7.04 4.52 15 18 33 22 39 49 41 30
Accounts Payable		 1.63 1.59 4.52 15 17 25 20 37 46 38 27
Other Current Liabilities		 - - - 0.00 0.96 2.27 2.55 2.51 2.72 2.86 2.92
Total Noncurrent Liabilities		 0.37 49 0.11 42 47 55 20 23 25 24 23
Other Noncurrent Operating Liabilities		 0.37 49 - 0.46 1.47 20 20 23 25 24 23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 109 73 16 194 307 504 455 490 493 463 277
Total Preferred & Common Equity		 109 73 16 194 307 504 455 490 493 463 277
Preferred Stock		 0.00 0.00 41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 109 73 -26 194 307 504 455 490 493 463 277
Common Stock		 305 312 5.41 301 490 826 947 1,204 1,452 1,681 1,718
Retained Earnings		 -196 -239 -31 -106 -183 -323 -492 -714 -959 -1,218 -1,441
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.05 0.00 -0.13 0.02 -0.04 -0.16 -0.36 0.32 0.07 -0.03

Quarterly Balance Sheets for Rocket Pharmaceuticals

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 417 515 462 599 499 446 394 471 421 368 285
Total Current Assets		 311 338 312 447 345 293 242 324 277 228 150
Cash & Equivalents		 197 65 45 226 35 39 66 50 33 76 50
Short-Term Investments		 110 267 262 212 295 240 170 268 239 147 95
Prepaid Expenses		 4.60 6.95 5.03 9.69 15 14 6.09 6.33 5.66 4.92 5.45
Plant, Property, & Equipment, net		 26 31 33 37 39 40 39 35 33 30 27
Total Noncurrent Assets		 81 146 117 115 115 114 113 112 111 111 109
Noncurrent Note & Lease Receivables		 47 46 46 45 44 43 43 42 41 41 40
Goodwill		 31 39 39 39 39 39 39 39 39 39 39
Intangible Assets		 - 26 26 25 25 25 25 25 25 25 25
Other Noncurrent Operating Assets		 2.83 6.17 6.25 6.00 6.66 6.39 6.21 5.88 5.71 5.53 4.95
Total Liabilities & Shareholders' Equity		 417 515 462 599 499 446 394 471 421 368 285
Total Liabilities		 50 56 59 58 58 62 64 59 67 54 47
Total Current Liabilities		 30 31 34 33 33 38 40 35 43 31 24
Accounts Payable		 28 29 31 31 30 35 37 32 41 28 22
Other Current Liabilities		 2.36 2.60 2.99 2.85 2.87 2.86 2.85 2.88 2.89 2.91 2.92
Total Noncurrent Liabilities		 20 25 24 24 25 24 24 24 23 23 23
Other Noncurrent Operating Liabilities		 20 25 24 24 25 24 24 24 23 23 23
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 367 459 403 541 442 385 330 412 354 314 238
Total Preferred & Common Equity		 367 459 403 541 442 385 330 412 354 314 238
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 367 459 403 541 442 385 330 412 354 314 238
Common Stock		 1,015 1,231 1,242 1,441 1,463 1,476 1,487 1,692 1,703 1,712 1,727
Retained Earnings		 -647 -772 -838 -900 -1,021 -1,091 -1,158 -1,279 -1,348 -1,399 -1,489
Accumulated Other Comprehensive Income / (Loss)		 -0.60 -0.09 -0.72 -0.51 -0.14 -0.22 0.21 -0.03 -0.11 -0.01 -0.11

Annual Metrics And Ratios for Rocket Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 26,410,251.00 26,930,730.00 27,222,745.00 39,835,500.00 50,376,030.00 55,233,798.00 64,442,601.00 - - - 108,222,228.00
DEI Adjusted Shares Outstanding		 6,602,563.00 6,732,683.00 6,805,686.00 39,835,500.00 50,376,030.00 55,233,798.00 64,442,601.00 - - - 108,222,228.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.26 -1.12 -2.88 -1.87 -1.53 -2.53 -2.62 - - - -2.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -137.12% 62.98% -160.66% -246.32% -6.43% -72.92% -26.88% -37.82% -20.48% -3.49% 16.26%
EBIT Growth		 -138.52% 62.87% -161.05% -259.88% -7.02% -76.36% -24.53% -34.14% -15.74% -5.22% 15.17%
NOPAT Growth		 -164.75% 62.87% -161.05% -259.88% -7.02% -76.36% -24.53% -34.14% -15.74% -5.22% 15.17%
Net Income Growth		 -613.27% 88.86% -158.52% -280.62% -3.69% -80.79% -21.02% -31.23% -10.70% -5.35% 13.77%
EPS Growth		 72.49% 88.86% -158.52% 34.38% 16.40% -59.49% -5.95% -22.10% 10.43% 6.51% 26.37%
Operating Cash Flow Growth		 -78.75% 68.40% -190.06% -236.98% -20.22% -15.43% -62.33% -47.03% -9.42% -7.60% 9.40%
Free Cash Flow Firm Growth		 0.00% 440.17% -242.83% -18.11% -5.88% -34.52% -14.83% -48.04% 3.10% -13.10% 19.56%
Invested Capital Growth		 -101.88% -2,011.92% 94.97% 952.15% 115.78% 25.94% 8.63% 36.42% -7.01% 8.59% -2.87%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -39.07% 8.89% -36.96% 8.12% -16.06% -1.24% 3.53% 7.60%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -38.80% 8.30% -41.80% 8.18% -12.40% 2.19% 0.21% 7.48%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -38.80% 8.30% -41.80% 8.18% -12.40% 2.19% 0.21% 7.48%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -37.88% 8.81% -41.63% 8.97% -11.27% 2.80% -0.26% 7.38%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -40.00% 5.95% -40.78% 13.31% -6.89% 8.46% 0.00% 10.67%
Operating Cash Flow Q/Q Growth		 -30.25% 83.41% -249.85% -38.05% 1.64% 8.15% -17.26% -16.39% 12.04% -9.16% 5.99%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -15.07% -17.19% 7.10% -32.85% 23.37% -9.12% 7.27%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -9.77% 36.04% 1.15% 2.78% 48.10% -19.45% -3.41% -2.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 315.65% 100.00% 99.03% 98.69% 98.19% 100.00% 101.14% 99.80% 95.84% 96.97% 96.83%
Interest Burden Percent		 105.59% 99.99% 99.99% 106.11% 103.34% 104.02% 99.95% 99.10% 98.69% 97.66% 99.43%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -130.67% -8.32% -44.15% -71.12% -30.83% -34.46% -35.29% -46.98% -50.01% -54.14% -60.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -334.58% -224.37% -195.50% -193.04% -232.14% -201.99% -227.30% -178.15%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -71.90% -8.32% -23.51% -57.05% -30.83% -34.46% -35.29% -46.98% -50.01% -54.14% -60.27%
Return on Equity Simple (ROE_SIMPLE)		 -62.48% -10.35% -126.16% -38.40% -25.15% -27.74% -37.18% -45.31% -49.86% -55.86% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -5.30 -14 -50 -53 -94 -117 -157 -182 -191 -162
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -99.69% -1.92% -8.00% -26.03% -11.13% -13.02% -12.51% -16.44% -15.79% -17.28% -21.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -32.07% -36.90% -41.28% -58.52%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -7.57 -20 -71 -76 -134 -167 -224 -260 -273 -232
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -7.51 -20 -68 -72 -125 -158 -218 -263 -272 -228
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.75 2.25 0.00 3.04 3.73 6.02 3.09 3.02 5.49 2.47 1.37
Price to Tangible Book Value (P/TBV)		 2.75 2.25 0.00 3.62 4.15 6.41 3.32 3.49 6.31 2.87 1.78
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 18.73 18.40 42.58 15.43 12.01 27.41 8.51 2.16
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.21 0.15 0.08 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.21 0.15 0.07 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.30 -1.62 -0.91 -0.86 -0.87 -0.87 -0.83 -0.82 -0.82 -0.76
Leverage Ratio		 1.14 1.34 1.69 1.30 1.24 1.19 1.14 1.11 1.14 1.14 1.16
Compound Leverage Factor		 1.21 1.34 1.69 1.37 1.29 1.24 1.13 1.10 1.12 1.12 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 17.60% 12.79% 7.35% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.90% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 17.60% 12.79% 6.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 267.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% -167.20% 82.40% 87.21% 92.65% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.61 -0.62 -0.32 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 2.53 3.59 3.55 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.61 -0.62 -0.28 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.83 -0.85 -0.42 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 3.45 4.86 4.71 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.83 -0.85 -0.37 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 37.96 0.10 4.65 5.59 10.18 20.23 18.35 11.86 18.79 6.49 -3.55
Noncontrolling Interest Sharing Ratio		 44.98% 0.00% 46.76% 19.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 27.14 18.23 4.19 13.60 16.81 14.94 17.69 9.29 7.80 9.30 6.38
Quick Ratio		 26.87 17.96 4.01 13.38 16.61 14.80 17.54 9.10 7.69 9.15 6.25
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -13 44 -63 -75 -79 -107 -122 -181 -175 -198 -160
Operating Cash Flow to CapEx		 -4,227.18% -1,642.69% -2,100.26% -3,753.52% -277.89% -362.21% -1,590.07% -2,131.40% -1,185.91% -3,662.02% -43,185.00%
Free Cash Flow to Firm to Interest Expense		 -10.60 0.00 0.00 -12.38 -13.29 -15.29 -41.09 -97.25 -93.57 -105.21 -84.41
Operating Cash Flow to Interest Expense		 -14.16 0.00 0.00 -8.91 -10.85 -10.71 -40.70 -95.67 -103.96 -111.20 -100.48
Operating Cash Flow Less CapEx to Interest Expense		 -14.49 0.00 0.00 -9.14 -14.76 -13.67 -43.26 -100.16 -112.72 -114.24 -100.72
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.47 -52 -2.62 22 48 61 66 90 84 91 88
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.25 -50 49 25 26 13 5.24 24 -6.31 7.19 -2.61
Enterprise Value (EV)		 188 38 94 419 887 2,586 1,018 1,081 2,295 774 191
Market Capitalization		 299 164 71 590 1,147 3,029 1,407 1,481 2,702 1,146 380
Book Value per Share		 $4.12 $2.72 ($0.95) $4.87 $6.10 $9.12 $7.06 $6.47 $5.46 $5.08 $2.56
Tangible Book Value per Share		 $4.12 $2.72 ($0.95) $4.10 $5.49 $8.56 $6.58 $5.61 $4.75 $4.38 $1.97
Total Capital		 109 73 16 235 352 543 455 490 493 463 277
Total Debt		 0.00 0.00 0.00 41 45 40 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 41 45 35 0.00 0.00 0.00 0.00 0.00
Net Debt		 -111 -126 -18 -172 -259 -443 -389 -400 -407 -372 -189
Capital Expenditures (CapEx)		 0.41 0.34 0.76 1.43 23 21 7.62 8.36 16 5.73 0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.06 -5.17 -3.71 -12 -15 -23 -19 -32 -43 -35 -26
Debt-free Net Working Capital (DFNWC)		 108 121 14 194 289 460 370 325 330 337 163
Net Working Capital (NWC)		 108 121 14 194 289 455 370 325 330 337 163
Net Nonoperating Expense (NNE)		 54 2.27 5.74 25 24 46 52 65 64 68 61
Net Nonoperating Obligations (NNO)		 -111 -125 -18 -172 -259 -443 -389 -400 -409 -372 -189
Total Depreciation and Amortization (D&A)		 0.12 0.07 0.20 3.39 4.03 9.59 9.01 6.27 -3.07 1.31 4.05
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($14.88) ($6.41) ($4.36) ($1.89) ($1.58) ($2.52) ($2.67) ($3.26) ($2.92) ($2.73) ($2.01)
Adjusted Weighted Average Basic Shares Outstanding		 6.61M 6.83M 39.40M 45.11M 55.07M 61.78M 63.24M 68.15M 84.01M 94.81M 111.12M
Adjusted Diluted Earnings per Share		 ($14.88) ($6.41) ($4.36) ($1.89) ($1.58) ($2.52) ($2.67) ($3.26) ($2.92) ($2.73) ($2.01)
Adjusted Weighted Average Diluted Shares Outstanding		 6.61M 6.83M 39.40M 45.11M 55.07M 61.78M 63.24M 68.15M 84.01M 94.81M 111.12M
Adjusted Basic & Diluted Earnings per Share		 ($14.88) ($6.41) ($4.36) ($1.89) ($1.58) ($2.52) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.58M 6.68M 6.77M 39.38M 49.01M 55.38M 64.51M 79.35M 90.50M 106.63M 108.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -5.30 -14 -50 -53 -94 -117 -157 -182 -191 -160
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -16.58 0.00 0.00 -11.78 -12.78 -19.28 -56.18 -120.49 -138.48 -144.86 -122.55
NOPAT to Interest Expense		 -11.61 0.00 0.00 -8.25 -8.95 -13.49 -39.33 -84.34 -96.94 -101.40 -85.79
EBIT Less CapEx to Interest Expense		 -16.92 0.00 0.00 -12.02 -16.69 -22.23 -58.74 -124.97 -147.25 -147.90 -122.79
NOPAT Less CapEx to Interest Expense		 -11.94 0.00 0.00 -8.49 -12.85 -16.45 -41.89 -88.83 -105.71 -104.44 -86.02
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.90% 0.00% -0.05% 0.00% -0.02% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Rocket Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - 107,737,919.00 107,903,871.00 108,222,228.00 108,569,143.00
DEI Adjusted Shares Outstanding		 - - - - - - - 107,737,919.00 107,903,871.00 108,222,228.00 108,569,143.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.64 -0.47 -0.39 -0.44
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -3.75% -4.50% -7.60% -6.23% -17.07% 13.92% 9.54% 0.99% 26.53% 30.41% 26.95%
EBIT Growth		 -11.87% 8.40% -8.33% -7.21% -6.11% 0.92% 4.43% 3.48% 24.74% 29.88% 24.66%
NOPAT Growth		 -11.87% 8.40% -8.33% -7.21% -6.11% 0.92% 4.43% 3.48% 24.74% 29.88% 24.66%
Net Income Growth		 -7.17% 10.59% -6.38% -6.00% -7.79% -1.12% 1.16% 1.04% 24.56% 29.49% 22.40%
EPS Growth		 13.79% 30.34% 9.59% 9.76% 5.33% 0.00% 15.15% 16.22% 36.62% 38.71% 25.00%
Operating Cash Flow Growth		 -30.30% 47.63% 1.22% -5.81% 8.83% -60.00% 1.87% 9.03% 3.23% 25.78% 18.63%
Free Cash Flow Firm Growth		 -137.03% 47.52% 16.58% 20.91% 56.38% -34.46% 53.20% 56.55% 13.96% 44.85% -20.77%
Invested Capital Growth		 70.97% -7.01% 12.50% 10.30% -9.44% 8.59% -15.48% -21.83% -3.40% -2.87% -0.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 18.12% -21.54% -1.06% -17.22% 9.76% 10.64% 0.26% -18.66% 30.54% 15.36% -8.24%
EBIT Q/Q Growth		 4.84% 3.29% -6.47% -9.41% 5.82% 9.69% -2.70% -10.50% 26.57% 15.86% -10.35%
NOPAT Q/Q Growth		 4.84% 3.29% -6.47% -9.41% 5.82% 9.69% -2.70% -10.50% 26.57% 15.86% -10.35%
Net Income Q/Q Growth		 5.79% 3.62% -4.01% -12.23% 4.20% 9.58% -1.67% -12.37% 26.97% 15.49% -11.89%
EPS Q/Q Growth		 8.54% 17.33% -6.45% -12.12% 4.05% 12.68% 9.68% -10.71% 27.42% 15.56% -10.53%
Operating Cash Flow Q/Q Growth		 -12.34% 48.66% -93.79% 5.33% 3.20% 9.91% -18.85% 12.24% -2.97% 30.90% -30.29%
Free Cash Flow Firm Q/Q Growth		 -14.41% 57.29% -51.22% -3.30% 36.90% -31.67% 45.46% 4.11% -24.95% 15.60% -19.44%
Invested Capital Q/Q Growth		 8.32% -19.45% 30.69% -4.84% -11.06% -3.41% 3.38% -11.98% 9.91% -2.88% 6.08%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 96.45% 94.80% 95.74% 96.88% 97.30% 98.01% 96.55% 96.88% 96.77% 97.24% 97.48%
Interest Burden Percent		 98.09% 99.46% 96.20% 97.53% 98.77% 98.18% 98.66% 99.99% 99.55% 99.51% 100.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -55.63% -50.01% -55.38% -64.31% -59.27% -54.14% -60.45% -69.65% -74.88% -60.27% -64.41%
Cash Return on Invested Capital (CROIC)		 -278.04% -201.99% -188.30% -197.02% -183.66% -227.30% -167.61% -174.26% -186.07% -178.15% -160.73%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -55.63% -50.01% -55.38% -64.31% -59.27% -54.14% -60.45% -69.65% -74.88% -60.27% -64.41%
Return on Equity Simple (ROE_SIMPLE)		 -46.69% 0.00% -56.47% -65.84% -78.26% 0.00% -62.61% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -46 -44 -47 -52 -49 -44 -45 -50 -37 -31 -34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.33% -3.80% -4.31% -6.16% -5.39% -4.21% -5.02% -6.95% -6.00% -4.19% -5.90%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.99% - - - -9.47% -10.94% -14.06% -11.66% -11.10% -14.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -65 -63 -67 -74 -69 -63 -64 -71 -52 -44 -49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -59 -72 -65 -76 -69 -62 -61 -73 -51 -43 -46
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.05 5.49 5.50 5.08 5.10 2.47 1.73 0.75 1.12 1.37 1.63
Price to Tangible Book Value (P/TBV)		 3.46 6.31 6.44 6.10 6.33 2.87 2.04 0.91 1.41 1.78 2.24
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 11.67 27.41 18.87 15.84 15.35 8.51 4.18 0.00 1.42 2.16 2.61
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.82 -0.82 -0.77 -0.74 -0.77 -0.82 -0.76 -0.74 -0.71 -0.76 -0.71
Leverage Ratio		 1.12 1.14 1.13 1.15 1.14 1.14 1.14 1.17 1.18 1.16 1.16
Compound Leverage Factor		 1.10 1.13 1.08 1.12 1.13 1.12 1.12 1.17 1.18 1.15 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 15.53 19.94 22.59 15.70 11.69 7.81 3.72 -2.00 -1.27 -1.67 -2.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.35 7.80 10.47 7.79 6.05 9.30 9.19 6.39 7.30 6.38 6.12
Quick Ratio		 13.06 7.69 10.02 7.42 5.89 9.15 9.01 6.26 7.15 6.25 5.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -89 -38 -60 -61 -39 -51 -28 -27 -33 -28 -34
Operating Cash Flow to CapEx		 -1,227.67% -631.35% -2,793.91% -2,788.76% -3,281.05% -15,191.59% -15,326.92% -97,928.00% 0.00% -43,550.00% -48,810.75%
Free Cash Flow to Firm to Interest Expense		 -189.63 -80.82 -126.36 -130.53 -82.36 -107.98 -59.02 -56.47 -70.56 -59.55 -71.13
Operating Cash Flow to Interest Expense		 -121.85 -62.42 -120.71 -114.27 -110.62 -99.24 -118.20 -103.52 -106.60 -73.66 -95.97
Operating Cash Flow Less CapEx to Interest Expense		 -131.78 -72.31 -125.03 -118.37 -113.99 -99.90 -118.97 -103.62 -106.48 -73.83 -96.17
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 104 84 111 106 94 91 94 83 91 88 94
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 43 -6.31 12 9.88 -9.81 7.19 -17 -23 -3.20 -2.61 -0.31
Enterprise Value (EV)		 1,213 2,295 2,099 1,676 1,445 774 393 -7.54 129 191 244
Market Capitalization		 1,650 2,702 2,429 1,955 1,680 1,146 711 264 352 380 389
Book Value per Share		 $6.72 $5.46 $4.72 $4.24 $3.62 $5.08 $3.87 $3.29 $2.91 $2.56 $2.19
Tangible Book Value per Share		 $5.92 $4.75 $4.03 $3.53 $2.92 $4.38 $3.26 $2.69 $2.31 $1.97 $1.60
Total Capital		 541 493 442 385 330 463 412 354 314 277 238
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -437 -407 -330 -279 -236 -372 -318 -271 -223 -189 -144
Capital Expenditures (CapEx)		 4.66 4.65 2.04 1.93 1.59 0.31 0.36 0.05 -0.05 0.08 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -24 -43 -18 -24 -34 -35 -29 -38 -26 -26 -19
Debt-free Net Working Capital (DFNWC)		 413 330 312 255 202 337 289 234 197 163 125
Net Working Capital (NWC)		 413 330 312 255 202 337 289 234 197 163 125
Net Nonoperating Expense (NNE)		 16 15 15 18 18 16 16 19 14 12 14
Net Nonoperating Obligations (NNO)		 -437 -409 -330 -279 -236 -372 -318 -271 -223 -189 -144
Total Depreciation and Amortization (D&A)		 6.59 -8.23 2.25 -2.63 0.54 1.14 2.99 -1.71 1.64 1.13 2.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56) ($0.62) ($0.45) ($0.38) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M 111.02M 111.57M 111.12M 112.13M
Adjusted Diluted Earnings per Share		 ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56) ($0.62) ($0.45) ($0.38) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding		 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M 111.02M 111.57M 111.12M 112.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 90.16M 90.50M 90.78M 90.98M 91.16M 106.63M 107.74M 107.90M 108.22M 108.57M 109.19M
Normalized Net Operating Profit after Tax (NOPAT)		 -46 -44 -47 -52 -49 -44 -45 -47 -37 -31 -34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -139.51 -134.64 -143.05 -156.50 -147.40 -132.55 -136.42 -150.42 -110.46 -92.95 -102.56
NOPAT to Interest Expense		 -97.66 -94.25 -100.13 -109.55 -103.18 -92.78 -95.49 -105.29 -77.32 -65.06 -71.79
EBIT Less CapEx to Interest Expense		 -149.43 -144.52 -147.37 -160.60 -150.77 -133.20 -137.19 -150.53 -110.34 -93.11 -102.76
NOPAT Less CapEx to Interest Expense		 -107.58 -104.13 -104.45 -113.65 -106.55 -93.44 -96.26 -105.40 -77.21 -65.23 -71.99
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rocket Pharmaceuticals (NASDAQ: RCKT) continues to look like a classic development-stage biotech: no revenue, heavy research spending, and a balance sheet that is still being drawn down by ongoing losses.

For Q1 2026, the company reported zero revenue and a net loss of $47.6 million, or $(0.42) per share. Operating expenses totaled $48.5 million, led by $31.5 million in R&D and $17.1 million in SG&A. Cash used in operations was $45.4 million, which shows the business is still burning significant cash to advance its pipeline.

At the same time, Rocket’s balance sheet remains substantial. As of March 31, 2026, the company held $49.6 million in cash and $94.8 million in short-term investments, for about $144.4 million in liquid assets. Total assets were $285.4 million, while total liabilities were $47.4 million. That leaves the company with a relatively clean balance sheet for a biotech, although the cash runway still deserves attention given the pace of losses.

Compared with recent quarters, Q1 2026 showed slightly improved operating spending versus Q4 2025 and some prior 2025 quarters, but not enough to change the broader story. Losses remain persistent, and dilution has been a major part of the company’s financing profile over the last several years.

  • Strong liquidity position: Rocket ended Q1 2026 with about $144.4 million in cash and short-term investments.
  • Low debt burden: Total liabilities of $47.4 million are modest relative to total assets of $285.4 million.
  • Investments supported cash flow: The company generated $17.4 million of investing cash flow in the quarter, helped by $66.3 million in investment sales.
  • No revenue yet: The company still reported $0 in revenue, so value depends entirely on pipeline progress.
  • Operating loss remains large: Q1 2026 operating loss was $48.5 million, showing the cost structure is still heavy.
  • Cash burn remains elevated: Operating cash outflow was $45.4 million in Q1 2026.
  • R&D is still the main expense: Research and development spending was $31.5 million, consistent with a pipeline-focused biotech.
  • Net loss widened versus cash generation: The company lost $47.6 million in Q1 2026, which is not close to being offset by operating activity.
  • Share count has trended higher over time: Basic weighted average shares were 112.1 million in Q1 2026 versus about 79.5 million in Q1 2023, reflecting dilution.
  • Long-term profitability is still distant: Across the last four years, Rocket has consistently posted quarterly losses, with no sign of recurring revenue.

Bottom line: Rocket Pharmaceuticals has enough assets to keep operating near term, but the financial picture is still defined by cash consumption, no revenue, and ongoing dilution risk. For investors, the stock remains a high-risk, pipeline-driven story where clinical and regulatory progress will matter far more than current fundamentals.

07/21/26 12:31 AM ETAI Generated. May Contain Errors.

Rocket Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rocket Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Rocket Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$223.12 million in 2025, rising from -$67.98 million in 2015. The previous period was -$258.75 million in 2024.

Rocket Pharmaceuticals' total operating income in 2025 was -$231.75 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $231.75 million

Over the last 10 years, Rocket Pharmaceuticals' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Rocket Pharmaceuticals' total liabilities were at $53.23 million at the end of 2025, a 17.4% decrease from 2024, and a 1,080.7% increase since 2015.

In the past 10 years, Rocket Pharmaceuticals' cash and equivalents has ranged from $18.14 million in 2017 to $297.10 million in 2020, and is currently $77.56 million as of their latest financial filing in 2025.

Over the last 10 years, Rocket Pharmaceuticals' book value per share changed from 4.12 in 2015 to 2.56 in 2025, a change of -37.8%.


Related Companies

Financial statements for NASDAQ:RCKTW last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Sam Altman backs small company that could save U.S. power grid
A small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...
Altimetry | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
NVIDIA offered $40B. The answer was no.
Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...
Behind the Markets | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel